DK2363130T3 - Kombination af HMG-CoA reduktaseinhibitorer atorvastatin eller simvastatin med en phosphodiesterase 4-inhibitor, såsom roflumilast til behandlingen af inflammatorisk pulmonære sygdomme - Google Patents

Kombination af HMG-CoA reduktaseinhibitorer atorvastatin eller simvastatin med en phosphodiesterase 4-inhibitor, såsom roflumilast til behandlingen af inflammatorisk pulmonære sygdomme

Info

Publication number
DK2363130T3
DK2363130T3 DK11164518.0T DK11164518T DK2363130T3 DK 2363130 T3 DK2363130 T3 DK 2363130T3 DK 11164518 T DK11164518 T DK 11164518T DK 2363130 T3 DK2363130 T3 DK 2363130T3
Authority
DK
Denmark
Prior art keywords
hmg
inhibitor
coa reductase
roflumilast
simvastatin
Prior art date
Application number
DK11164518.0T
Other languages
English (en)
Inventor
Stefan-Lutz Wollin
Andrea Wohlsen
Degenhard Marx
Clemens Braun
Original Assignee
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Gmbh filed Critical Takeda Gmbh
Application granted granted Critical
Publication of DK2363130T3 publication Critical patent/DK2363130T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK11164518.0T 2006-07-05 2007-07-03 Kombination af HMG-CoA reduktaseinhibitorer atorvastatin eller simvastatin med en phosphodiesterase 4-inhibitor, såsom roflumilast til behandlingen af inflammatorisk pulmonære sygdomme DK2363130T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06116625 2006-07-05
EP07787007A EP2040707B1 (en) 2006-07-05 2007-07-03 Combination of atorvastatin with a phosphodiesterase 4 inhibitor for the treatment of inflammatory pulmonary diseases

Publications (1)

Publication Number Publication Date
DK2363130T3 true DK2363130T3 (da) 2014-07-21

Family

ID=37311957

Family Applications (2)

Application Number Title Priority Date Filing Date
DK11164516.4T DK2359826T3 (da) 2006-07-05 2007-07-03 Kombination af HMG-reduktaseinhibitor rosuvastatin med en phosphodiesterase-4-inhibitor, såsom roflumilast, roflumilast-N-oxid til behandlingen af inflammatoriske pulmonale sygdomme
DK11164518.0T DK2363130T3 (da) 2006-07-05 2007-07-03 Kombination af HMG-CoA reduktaseinhibitorer atorvastatin eller simvastatin med en phosphodiesterase 4-inhibitor, såsom roflumilast til behandlingen af inflammatorisk pulmonære sygdomme

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK11164516.4T DK2359826T3 (da) 2006-07-05 2007-07-03 Kombination af HMG-reduktaseinhibitor rosuvastatin med en phosphodiesterase-4-inhibitor, såsom roflumilast, roflumilast-N-oxid til behandlingen af inflammatoriske pulmonale sygdomme

Country Status (26)

Country Link
US (2) US20100069392A1 (da)
EP (3) EP2359826B1 (da)
JP (3) JP5349302B2 (da)
KR (1) KR101433394B1 (da)
CN (3) CN102764440A (da)
AT (1) ATE535244T1 (da)
AU (1) AU2007271186C1 (da)
BR (1) BRPI0713768A2 (da)
CA (1) CA2656366A1 (da)
CY (2) CY1114742T1 (da)
DK (2) DK2359826T3 (da)
EA (2) EA032476B1 (da)
ES (3) ES2489265T3 (da)
HR (2) HRP20140073T1 (da)
IL (3) IL195433A (da)
ME (2) ME01901B (da)
MX (1) MX2008016123A (da)
NO (1) NO342590B1 (da)
NZ (3) NZ573378A (da)
PL (2) PL2359826T3 (da)
PT (2) PT2363130E (da)
RS (2) RS53084B (da)
SI (2) SI2359826T1 (da)
UA (3) UA101556C2 (da)
WO (1) WO2008003701A2 (da)
ZA (1) ZA200809905B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0909288A2 (pt) * 2008-03-14 2015-08-18 Otsuka Pharma Co Ltd Inibidores da mmp-2 e/ou da mmp-9
CN102671198A (zh) * 2011-12-17 2012-09-19 东莞达信生物技术有限公司 一种降压降脂复方药及其制备方法
US10508307B2 (en) 2014-06-05 2019-12-17 Transgenion—International Institute for Regenerative Translational Medicine GmbH Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers
JP6755240B2 (ja) * 2014-06-05 2020-09-16 トランスゲニオン−インターナショナル インスティテュート フォー リジェネレイティヴ トランスレイショナル メディシン ゲーエムベーハー 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法
WO2015185658A2 (en) 2014-06-05 2015-12-10 Medizinische Universität Wien Methods of diagnosing chronic obstructive pulmonary disease (copd) using novel molecular biomarkers
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
WO2020106754A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2021218988A1 (zh) * 2020-04-30 2021-11-04 中国科学院上海药物研究所 Prdx1激动剂及其用途
CN117504071A (zh) * 2022-08-03 2024-02-06 奇斯药制品公司 干粉吸入器

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR69216B (da) 1979-06-15 1982-05-07 Merck & Co Inc
AU548996B2 (en) 1980-02-04 1986-01-09 Merck & Co., Inc. Tetrahydro-2h-pyran-2-one derivatives
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
AU570021B2 (en) 1982-11-22 1988-03-03 Novartis Ag Analogs of mevalolactone
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI90236C (fi) 1987-07-10 1994-01-10 Hoechst Ag Menetelmä terapeuttisesti käyttökelpoisten 3-desmetyylimevalonihappojohdannaisten valmistamiseksi
CA1336714C (en) 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
US4863957A (en) 1987-12-21 1989-09-05 Rorer Pharmaceutical Corporation Novel HMG-CoA reductase inhibitors
FR2642065B1 (fr) 1989-01-24 1991-05-24 Lipha Derives d'acides benzocycloalcenyl dihydroxy alcanoiques, procede de preparation et medicaments les contenant
DE69132006T2 (de) 1990-11-30 2000-08-03 Otsuka Pharma Co Ltd Thiazolederivate als inhibitoren von aktivem sauerstoff
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
DE69332987T2 (de) * 1992-04-02 2004-05-19 Smithkline Beecham Corp. Verbindungen verwendbar für die Behandlung von Allergien und Entzündungskrankheiten
NZ251092A (en) 1992-04-02 1996-12-20 Smithkline Beecham Corp 4-cyano-cyclohexane derivatives; medicaments; used in treating asthma
CA2165192C (en) * 1993-07-02 2001-04-24 Hermann Amschler Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
GB9504460D0 (en) 1995-03-06 1995-04-26 Bayer Ag N-(3-Benzofuranyl)urea-derivatives
SK282167B6 (sk) 1995-06-06 2001-11-06 Pfizer Inc. Tricyklické 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a] pyridíny a farmaceutický prostriedok na ich báze
DE19636150A1 (de) 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
ES2262072T3 (es) 1998-04-28 2006-11-16 Elbion Ag Derivados de indol y su utilizacion como inhibidores de la fosfodiesterasa 4.
US20010006656A1 (en) 1999-02-17 2001-07-05 University Of Washington Methods and compositions for inhibiting inflammation associated with pulmonary disease
DE19944161A1 (de) 1999-09-15 2001-03-22 Bayer Ag Neue Kombination zur Behandlung von sexueller Dysfunktion
US6410563B1 (en) * 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
MY134008A (en) 1999-12-22 2007-11-30 Merck Frosst Canada Inc Subtituted 8-arylquinoline phospohodiestrase-4 inhibitors
US20030018040A1 (en) 2000-02-10 2003-01-23 Yasuo Sugiyama Tnf-alpha inhibitors
JP2001294526A (ja) * 2000-02-10 2001-10-23 Takeda Chem Ind Ltd ＴＮＦ−α抑制剤
MY123585A (en) 2000-03-23 2006-05-31 Merck Canada Inc Tri-aryl-substituted-ethane pde4 inhibitors.
US20050102317A1 (en) * 2000-07-21 2005-05-12 Ali Kamarei System and method for event calendaring using a customizable rules subset
CA2422820A1 (en) * 2000-09-19 2002-03-28 Novimmune S.A. Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
US6740666B2 (en) * 2000-12-20 2004-05-25 Merck & Co., Inc. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
EE05386B1 (et) 2001-02-15 2011-02-15 ALTANA�Pharma�AG Ftalasinoon-piperidinoderivaadid,ÁnendeÁkasutamineÁjaÁravim
WO2002069906A2 (en) * 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
JP4193435B2 (ja) * 2002-07-23 2008-12-10 ブラザー工業株式会社 インクカートリッジ、および、そのインク充填方法
ATE303384T1 (de) * 2001-05-24 2005-09-15 Merck Frosst Canada Inc 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
CA2450686A1 (en) * 2001-06-27 2003-01-09 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Substituted 8-arylquinoline pde4 inhibitors
US20030114469A1 (en) 2001-09-27 2003-06-19 Cohen David Saul Combinations
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US20060004056A1 (en) * 2002-07-02 2006-01-05 Bernard Cote Di-aryl-substituted-ethan pyridone pde4 inhibitors
MXPA05005161A (es) * 2002-11-18 2005-07-22 Celgene Corp Metodos de utilizacion y composiciones que comprenden (-)3- (3, 4-dimetoxi- fenil)-3 -(1-oxo -1, 3-dihidro- isoindol- 2-il)- propionamida.
IS7839A (is) 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar
RS51081B (sr) * 2002-11-27 2010-10-31 Nycomed Gmbh. Nova sinergistička kombinacija koja uključuje roflumilast i formoterol
US20050119330A1 (en) * 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
US20040254238A1 (en) * 2003-04-07 2004-12-16 Osteoscreen Bone growth stimulation with NO/statin and other NO modulating combinations
BRPI0409747A (pt) 2003-04-11 2006-05-09 Glenmark Pharmaceuticals Sa novos compostos heterocìclicos úteis para tratamento de distúrbios inflamatórios e alérgicos, processo para sua preparação e composições farmacêuticas contendo estes
JP2006524638A (ja) * 2003-04-30 2006-11-02 メルク フロスト カナダ リミテツド ８−（３−ビアリール）フェニルキノリン系ホスホジエステラーゼ−４阻害薬
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
NZ544040A (en) * 2003-05-22 2009-03-31 Nycomed Gmbh Composition comprising a PDE4 inhibitor and a PDE5 inhibitor
EP1635813A4 (en) * 2003-06-06 2009-07-01 Merck & Co Inc COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA
US20060160834A1 (en) * 2003-06-06 2006-07-20 Fong Tung M Combination therapy for the treatment of hypertension
DE10348646A1 (de) 2003-10-15 2005-05-25 Gkn Driveline International Gmbh Rollbalg mit großem Krümmungsradius
AU2005235306B2 (en) * 2004-04-19 2008-08-21 Loma Linda University Composition and method of decreasing renal ischemic damage
JP2007533760A (ja) * 2004-04-23 2007-11-22 セルジーン・コーポレーション 肺高血圧症を治療し管理するための、ｐｄｅ４モジュレーターの使用方法及びｐｄｅ４モジュレーターを含む組成物
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
GB0415789D0 (en) * 2004-07-15 2004-08-18 Astrazeneca Ab Novel combination
DE102004046236A1 (de) 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
GB0508924D0 (en) 2005-04-30 2005-06-08 Astrazeneca Ab New use
GB0510207D0 (en) 2005-05-19 2005-06-22 Astrazeneca Ab Novel combination
PL1894576T3 (pl) 2005-06-08 2011-10-31 Kowa Co Nowy środek do obniżania poziomu triglicerydów
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AR057555A1 (es) * 2005-10-27 2007-12-05 Merck Frosst Canada Ltd Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo
US8026377B2 (en) 2005-11-08 2011-09-27 Ranbaxy Laboratories, Limited Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
WO2008036846A2 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis

Also Published As

Publication number Publication date
CN102764440A (zh) 2012-11-07
CN102772411A (zh) 2012-11-14
UA106422C2 (uk) 2014-08-26
AU2007271186C1 (en) 2013-08-15
NZ573378A (en) 2012-03-30
KR101433394B1 (ko) 2014-08-26
UA98466C2 (uk) 2012-05-25
ES2443342T3 (es) 2014-02-19
US9713614B2 (en) 2017-07-25
ME01901B (me) 2014-12-20
NZ603207A (en) 2013-12-20
EP2040707B1 (en) 2011-11-30
EP2359826A1 (en) 2011-08-24
JP2013035871A (ja) 2013-02-21
SI2359826T1 (sl) 2014-02-28
JP5349302B2 (ja) 2013-11-20
CY1115462T1 (el) 2017-01-04
MX2008016123A (es) 2009-01-15
ATE535244T1 (de) 2011-12-15
EP2359826B1 (en) 2013-10-30
EP2363130B1 (en) 2014-05-07
PT2363130E (pt) 2014-06-25
RS53084B (en) 2014-06-30
ES2378281T3 (es) 2012-04-10
UA101556C2 (uk) 2013-04-10
NO20090370L (no) 2009-02-04
US20100069392A1 (en) 2010-03-18
US20150272949A1 (en) 2015-10-01
CN101484166B (zh) 2012-09-05
KR20090025368A (ko) 2009-03-10
IL221307A (en) 2014-08-31
HRP20140073T1 (hr) 2014-02-28
IL195433A0 (en) 2009-08-03
EA201401042A1 (ru) 2016-05-31
JP2009541459A (ja) 2009-11-26
CN101484166A (zh) 2009-07-15
PL2359826T3 (pl) 2014-04-30
DK2359826T3 (da) 2014-01-20
WO2008003701A3 (en) 2008-03-13
IL221309A (en) 2014-12-31
ES2489265T3 (es) 2014-09-01
EA021461B1 (ru) 2015-06-30
AU2007271186B2 (en) 2013-01-17
BRPI0713768A2 (pt) 2012-10-30
IL221307A0 (en) 2012-09-24
NO342590B1 (no) 2018-06-18
SI2363130T1 (sl) 2014-09-30
ZA200809905B (en) 2009-11-25
WO2008003701A2 (en) 2008-01-10
CA2656366A1 (en) 2008-01-10
AU2007271186A1 (en) 2008-01-10
EP2363130A1 (en) 2011-09-07
ME01648B (me) 2014-09-20
PT2359826E (pt) 2014-01-20
EP2040707A2 (en) 2009-04-01
PL2363130T3 (pl) 2014-09-30
CY1114742T1 (el) 2016-12-14
NZ594369A (en) 2013-10-25
JP2013035870A (ja) 2013-02-21
EA200900073A1 (ru) 2009-06-30
HRP20140707T1 (hr) 2014-09-12
IL195433A (en) 2013-02-28
EA032476B1 (ru) 2019-06-28
RS53461B (en) 2014-12-31

Similar Documents

Publication Publication Date Title
DK2363130T3 (da) Kombination af HMG-CoA reduktaseinhibitorer atorvastatin eller simvastatin med en phosphodiesterase 4-inhibitor, såsom roflumilast til behandlingen af inflammatorisk pulmonære sygdomme
EA200702358A1 (ru) Комбинация ингибитора pde4 и производного тетрагидробиоптерина
DE602006010243D1 (de) 4-(Phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamid Derivate als MEK Inhibitoren zur Behandlung von hyperproliferativen Erkrankungen
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
ATE530540T1 (de) Pyrimidonverbindungen als gsk-3-inhibitoren
WO2007015866A3 (en) Inhibitors of p38 kinase and methods of treating inflammatory disorders
WO2008011560A3 (en) Benzothiophene inhibitors of rho kinase
ATE496029T1 (de) Derivate von 1-phenyl-2-pyridinylalkylenalkohole als phosphodiesteraseinhibitoren
IL190346A0 (en) Pharmaceutical preparation having excellent photostability
WO2007015877A3 (en) Inhibitors of p38 kinase and methods of treating inflammatory disorders
EA200800070A1 (ru) Производные 2-(1h-индолилсульфанил)ариламина
DK1879862T3 (da) Magnesiumsalte af HMG-COA reduktaseinhibitorer
EA200801666A1 (ru) КОМБИНАЦИЯ ПРОИЗВОДНЫХ ТРИАЗИНА И ИНГИБИТОРОВ HMG-CoA РЕДУКТАЗЫ
EP1871396A4 (en) STABILIZED PHARMACEUTICAL COMPOSITIONS WITH AN HMG COA REDUCTASE INHIBITOR
ITTO20050010A1 (it) Corpo illuminante o di pronto soccorso applicato su inibitori di fiamma ad aerosol
ES1060975Y (es) Rampa salva-bordes de acera perfeccionada.